FDA Hands Fast-Track Voucher for Kid's Rare Liver Fix
Published Date: 4/7/2026
Notice
Summary
The FDA just gave a special fast-track ticket called a Priority Review Voucher to Immedica Pharma AB for their rare pediatric disease drug, LOARGYS, approved in February 2026. This voucher helps speed up future drug reviews, benefiting patients with rare diseases and encouraging companies to develop more treatments. It’s a big win for kids with Arginase 1 Deficiency and could speed up new medicines hitting the market.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
New FDA Approval for ARG1‑D
The FDA approved LOARGYS (pegzilarginase-nbln) on February 23, 2026 to treat hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency. The drug is indicated to be used in conjunction with dietary protein restriction.
Priority Review Voucher Issued
The FDA issued a Priority Review Voucher to the sponsor, Immedica Pharma AB, tied to the approval of LOARGYS on February 23, 2026. The award is made under section 529 of the Federal Food, Drug, and Cosmetic Act to sponsors of approved rare pediatric disease product applications that meet certain criteria.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-06721, Caribbean Fishery Management Council 189th Public Hybrid Meeting
The Caribbean Fishery Management Council is holding its 189th meeting on April 21-22, 2026, both in person in St. Croix and online. Fishermen, local businesses, and seafood lovers will hear updates on fishery plans and science, with possible changes that could affect fishing rules and local economies. This meeting sets the stage for important decisions that could impact fishing seasons and community incomes soon.
Next: 2026-06723, Notice of OFAC Sanctions Actions
The U.S. Treasury’s OFAC just updated its sanctions list by removing Globe Trekkers LLC and Carlos Arnoldo Lobo, unblocking their property and interests. This means these folks are no longer restricted by U.S. sanctions, which could open up new business or financial opportunities. These changes took effect in early March 2026, so watch for any money moves or deals involving them!